SCHEMBL4167662

SCHEMBL4167662

COc1ccc(-c2cnn3c(N)c(-c4cccc(Cl)c4)c(CN4CCNCC4)nc23)cc1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 1/20 0.59
RET P07949 8/20 0.55
KIF5B P33176 8/20 0.55
KDR P35968 7/20 0.55
ETV6 P41212 5/20 0.55
CCDC6 Q16204 4/20 0.55
LCK P06239 3/20 0.49
CSF1R P07333 3/20 0.49
LYN P07948 3/20 0.49
PDGFRB P09619 3/20 0.49
FGR P09769 3/20 0.49
KIT P10721 3/20 0.49
SRC P12931 3/20 0.49
PDGFRA P16234 3/20 0.49
FGFR2 P21802 3/20 0.49
BLK P51451 3/20 0.49
ABL1 P00519 2/20 0.49
NPM1 P06748 2/20 0.49
BCR P11274 2/20 0.49
FLT3 P36888 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4754706 0.88 FYN (0.43) FYNRETKIF5BKDRETV6
SCHEMBL4695372 0.87 RET (0.55) FYNRETKIF5BKDRETV6
SCHEMBL4695093 0.85 FYN (0.68) FYNRETKIF5BKDRETV6
SCHEMBL4171927 0.85 FYN (0.67) FYNRETKIF5BKDRETV6
SCHEMBL4179850 0.83 FYN (0.71) FYNRETKIF5BKDRETV6
SCHEMBL4695327 0.82 RET (0.43) FYNRETKIF5BKDRETV6
SCHEMBL4695452 0.80 FYN (0.60) FYNRETKIF5BKDRETV6
SCHEMBL4173163 0.76 FYN (0.47) FYNRETKIF5BKDRETV6
SCHEMBL30521695 0.75 FYN (1.00) FYNRETKIF5BKDRETV6
SCHEMBL18613401 0.75 FYN (1.00) FYNRETKIF5BKDRETV6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069315-A1 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders SIVASANKARAN RAJEEV 2009-03-12 US disclosed
US-20080234284-A1 Pyrazolo[1,5-a]Pyrimidin-7-Yl Amine Derivatives as Protein Kinase Inhibitors NOVARTIS AG (CH) 2008-09-25 US disclosed
EP-1910368-A1 PYRAZOLO[1.5-A]PYRIMIDIN-7-YL AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS Novartis AG (CH) 2008-04-16 EP disclosed
WO-2007009773-A1 PYRAZOLO[1.5-A]PYRIMIDIN-7-YL AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069315-A1 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders EPHA5, EPHA7, EPHA1 FYN 360/4885RET 252/4885KIF5B 1372/4885
US-20080234284-A1 Pyrazolo[1,5-a]Pyrimidin-7-Yl Amine Derivatives as Protein Kinase Inhibitors MAP3K5, MAP3K20, MAP3K7 FYN 391/4885RET 325/4885KIF5B 2389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.